I for one am not disappointed in the halt on the endometriosis research from a cash burn point of view. As a business attempting to be self funding it will be better to focus on a more rapid commercialisation of PromarkerD. If successful the revenue will fund anything else PIQ care to do. If PromarkerD is accepted as hoped there would be enough revenue to then fast track the endometriosis research.
To have a company at this stage of development having revenues sufficient to cover costs is a big deal. Building from here without needing a cash injection is a Hugh bonus to all current holders.
Ann: Appendix 4C - September 2019 Quarterly Report, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $49.87M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 30.0¢ | $14.68K | 48.93K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 13584 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 5380 | 1 |
View Market Depth
| Last trade - 10.34am 26/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |